These drugs are administered for melanomas and lung cancers harboring BRAF V600E mutations, and the combination showed meaningful responses in 33% of high-grade and 69% of low-grade gliomas in a Phase II clinical trial (144). This evidence concerns the gene BRAF and glioma.